Thoracic Cancer,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 18, 2024
Abstract
Background
Metastasis
to
the
thyroid
gland
from
lung
adenocarcinoma
is
rare
and
challenging
diagnose
due
similar
histopathological
features.
This
study
aimed
analyze
clinicopathological
characteristics
of
treatment
strategies
for
metastasis
based
on
11
years
institutional
experience.
Methods
A
retrospective
included
patients
with
at
our
center
2010
2023.
Clinicopathological
features
clinical
outcomes
were
analyzed.
Results
Among
9714
patients,
nine
(five
females,
55.6%)
diagnosed
metastasis,
presenting
primarily
cough
symptoms.
Most
(88.9%)
had
synchronous
tumors,
whereas
a
minority
(11.1%)
metachronous
tumors.
The
median
time
primary
tumor
diagnosis
was
4.8
months.
developed
bilateral
metastases
(88.9%).
Diagnosis
through
fine‐needle
aspiration
(FNA),
one
case
misdiagnosed
as
papillary
carcinoma.
Immunohistochemical
staining
revealed
transcription
factor‐1
(TTF‐1)
novel
aspartic
proteinase
pepsin
family
(Napsin‐A)
positivity
paired
box
8
(PAX8)
negativity.
Genetic
testing
found
epidermal
growth
factor
receptor
mutations
in
71.4%
patients.
individualized
comprehensive
therapy
surgery,
chemotherapy,
immunotherapy,
targeted
supportive
therapy.
overall
survival
56.0
months,
progression‐free
12.7
Kaplan–Meier
(K–M)
analysis
suggested
improved
no
advanced
symptoms
(
p
=
0.03)
therapies
0.05).
Conclusions
Lung
disease,
an
incidence
0.1%
among
Early
after
symptom
onset
personalized
may
improve
prognosis.
Despite
rapid
disease
progression,
favorable
can
be
achieved
treatment.
Cancer Immunology Immunotherapy,
Journal Year:
2025,
Volume and Issue:
74(3)
Published: Feb. 1, 2025
PD-1
blockade
plus
chemotherapy
has
become
the
first-line
standard
of
care
for
patients
with
advanced
non-small-cell
lung
cancer
(NSCLC)
without
oncogenic
drivers.
Oncogenic-driven
NSCLC
showed
limited
response
to
monotherapy
or
alone.
Whether
drivers
could
benefit
from
remains
undetermined.
Three
hundred
twelve
at
least
one
driver
alteration
received
each
were
retrospectively
identified.
Objective
rate
(ORR),
progression-free
survival
(PFS),
and
overall
(OS)
compared
evaluate
therapeutic
outcomes
differences
among
different
One
sixty-two
chemotherapy,
57
93
alone
included.
Oncogenic
mutations
including
KRAS
(31.4%),
EGFR
(28.8%),
HER2
(14.7%),
BRAF
(10.6%),
RET
(7.4%),
other
(7.1%)
Patients
who
had
significantly
better
those
(ORR:
51%
vs.
18%
25%,
P
<
0.001;
median
PFS:
10.0
[95%
CI:
8.9–12.6]
3.7
2.9–5.1]
5.3
4.5–6.2]
months,
OS:
26.0
23.0–30.0]
14.3
9.6–19.8]
16.1
11.6–21.9]
0.001).
The
superior
efficacy
was
consistently
found
in
separate
analyses
second/third
line
treatments.
Among
individual
gene
alterations,
KRAS,
EGFR,
treated
achieved
markedly
improved
PFS
OS
than
Multivariate
Cox
regression
analysis
revealed
that
independently
associated
OS.
demonstrated
oncogenic-driven
NSCLC,
particularly
subgroups.
These
findings
suggest
may
be
considered
as
an
optional
treatment
option
available
targeted
therapies.
Clinical Nuclear Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 24, 2025
Purpose:
This
study
was
designed
to
evaluate
68
Ga-pentixafor,
which
targets
C-X-C
chemokine
receptor
4
(CXCR4),
in
the
noninvasive
diagnosis
of
thymomas.
Patients
and
Methods:
With
institutional
review
board
approval
signed
informed
consent,
32
patients
with
thymic
masses
were
enrolled
this
study,
all
underwent
Ga-pentixafor
PET/CT
scans.
Results:
Among
28
included
analysis,
13
diagnosed
thymomas,
9
cysts,
6
other
anterior
mediastinal
masses.
identified
thymomas
(13/13,
100%),
mean
SUV
max
lesions
13.96±8.20,
significantly
higher
than
that
cysts
(1.54±0.88)
(2.59±1.68),
respectively
(
P
<0.001).
Conclusions:
The
preliminary
indicates
diagnostic
utility
differential
ability
benign
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 28, 2025
Neural
infiltration
has
been
found
in
various
cancers
and
the
infiltrating
nerves
influence
tumor
growth
dissemination.
In
non-small
cell
lung
cancer,
pan-neuronal
marker
PGP9.5
was
detected
by
immunohistochemical
staining
its
high
expression
correlated
with
poor
prognosis.
However,
existence
of
nerve
fibers
mechanism
driving
neural
remains
unclear.
We
first
used
to
assess
density
patients
adenocarcinoma
different
sizes.
Following
that,
we
performed
differential
analysis
univariate
Cox
prognostic
analysis,
using
public
datasets
experiments
identify
gene
that
triggers
is
associated
cancer
progression
unfavorable
Finally,
molecular
biology
a
subcutaneous
model
were
deeply
analyze
regulates
progression.
patients,
positive
within
tumors
larger
than
2
cm
diameter
significantly
higher
smaller
cm.
Bioinformatics
suggested
NGEF,
KIF4A,
PABPC1
could
be
genes
trigger
are
Subsequent
co-culture
neurons
showed
increased
NGEF
cells
enhanced
axonal
neurons.
Meanwhile,
GSE30219
indicated
exhibiting
levels
sizes,
lymph
node
involvement,
reduced
overall
survival
rates.
At
level
mechanisms,
knockdown
Ephrin-A3
ND7/23
or
use
ALW-II-41-27
resulted
significant
decrease
neurite
outgrowth
when
co-cultured
LA795
cells.
animal
model,
overexpression
promoted
fibers,
these
effects
inhibited
ALW-II-41-27.
facilitates
through
Ephrin-A3/EphA2
pathway,
suggesting
promising
target
for
disrupting
interactions
between
tumors.
Biomaterials
focus
on
anticipated
potential
treatment
option
cancer.
BMC Cancer,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: March 12, 2025
The
9th
edition
of
the
lung
cancer
tumor-node-metastasis
(TNM)
staging
system
downgrades
certain
non-small
cell
(NSCLC)
patients
from
stage
IIIA
(T1N2)
to
IIB(T1N2a).
This
study
aimed
externally
validate
this
adjustment.
Consecutive
resected
IIB
and
(the
TNM
manual)
NSCLC
were
included.
Stage
was
divided
into
groups
A,
B,
C
according
lymph
node
involvement.
Group
who
having
single-station
N2
without
N1
involvement;
with
involvements;
C,
station
involvement
or
N0.
D.
Overall
survival
(OS)
disease-free
(DFS)
compared
using
Kaplan-Meier
method,
propensity
score
matching
(PSM)
employed
mitigate
potential
biases.
COX
regression
models
utilized
assess
prognostic
differences.
224
227
cases
There
38,
66
120
in
B
respectively.
Univariate
analysis
indicated
comparable
prognoses
between
A
patients,
whereas
exhibited
poorer
outcomes.
Upon
combining
multivariate
demonstrated
a
significantly
worse
prognosis
for
those
+
(OS,
P
=
0.035;
DFS,
0.021).
Further
comparisons
D
following
PSM
analysis,
similar
survivals
(OS:
0.390;
DFS:
0.210).
In
system,
N2a2
than
that
remaining
but
patients.
We
proposed
should
be
maintained
as
IIIA.
Diagnostics,
Journal Year:
2025,
Volume and Issue:
15(7), P. 908 - 908
Published: April 1, 2025
Lung
cancer
is
a
prevalent
malignant
disease
with
the
highest
mortality
rate
among
oncological
conditions.
The
assessment
of
its
clinical
TNM
staging
primarily
relies
on
contrast-enhanced
computed
tomography
(CT)
thorax
and
proximal
abdomen,
sometimes
addition
positron
emission
tomography/CT
scans,
mainly
for
better
evaluation
mediastinal
lymph
node
involvement
detection
distant
metastases.
purpose
to
establish
universal
nomenclature
anatomical
extent
lung
cancer,
facilitating
interdisciplinary
communication
treatment
decisions
research
advancements.
Recent
studies
utilizing
large
international
database
multidisciplinary
insights
indicate
need
update
classification
enhance
categorization
ultimately
optimizing
strategies.
eighth
edition
classification,
issued
by
International
Association
Study
Cancer
(IASLC),
transitioned
ninth
1
January
2025.
Key
changes
include
more
detailed
N
M
descriptor
categories,
whereas
T
remains
unchanged.
Notably,
N2
category
will
be
split
into
N2a
N2b
based
single-station
or
multi-station
ipsilateral
and/or
subcarinal
nodes,
respectively.
M1c
differentiate
between
single
(M1c1)
multiple
(M1c2)
organ
system
extrathoracic
This
review
article
emphasizes
role
radiologists
in
implementing
updated
through
CT
imaging
correct
optimal
patient
management.
